AI Article Synopsis
- - Mesenchymal stem cells (MSCs) are being researched for their potential benefits in kidney transplantation due to their ability to help the immune system and promote healing.
- - Clinical trials have shown that MSCs are generally safe and well-tolerated when used around the time of kidney transplant, but there's limited information about their effects later on.
- - This case report describes a serious complication resembling capillary leak syndrome that led to kidney transplant failure after using MSCs as a last-ditch effort to treat late-stage rejection of a transplanted kidney.
Article Abstract
Mesenchymal stem cells (MSCs) have attracted great interest in the field of kidney transplantation due to their immunomodulatory and reparative properties. In registered clinical trials, MSCs have been used before, at the time of, or early after transplantation and have been reported to be well-tolerated with no serious safety concerns. No results are available on the use of MSCs in the late post-transplant period. Here, we present a case report of a severe systemic complication mimicking capillary leak syndrome with ultimate kidney transplant failure after autologous transplantation of MSCs used as rescue treatment of late antibody-mediated kidney allograft rejection.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8334176 | PMC |
| http://dx.doi.org/10.3389/fmed.2021.708744 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!